Autosomal dominant GTP cyclohydrolase I deficiency

A genetic disorder affecting dopamine and serotonin production

Autosomal dominant GTP cyclohydrolase I deficiency is a rare genetic disorder that affects the production of certain neurotransmitters in the brain. It is also known as dopa-responsive dystonia (DRD) due to its characteristic response to treatment with levodopa. This condition is caused by mutations in the GCH1 gene, which encodes the enzyme GTP cyclohydrolase I, a critical enzyme in the biosynthesis of tetrahydrobiopterin (BH4). BH4 is a cofactor necessary for the production of dopamine and serotonin, two important neurotransmitters.

Pathophysiology

Pattern of cerebrospinal fluid metabolites for Autosomal dominant GTP cyclohydrolase I deficiency

The GCH1 gene provides instructions for making the enzyme GTP cyclohydrolase I, which is involved in the first step of the biosynthesis of tetrahydrobiopterin (BH4). BH4 is essential for the hydroxylation of phenylalanine, tyrosine, and tryptophan, which are precursors to the neurotransmitters dopamine and serotonin. In individuals with autosomal dominant GTP cyclohydrolase I deficiency, mutations in the GCH1 gene lead to reduced activity of the enzyme, resulting in decreased levels of BH4. This deficiency impairs the production of dopamine and serotonin, leading to the symptoms associated with the disorder.

Clinical Features

The clinical presentation of autosomal dominant GTP cyclohydrolase I deficiency is highly variable, even among individuals within the same family. The most common symptom is dystonia, which typically begins in childhood and often affects the lower limbs. This can lead to difficulties with walking and other motor activities. The dystonia is often "dopa-responsive," meaning that it improves significantly with treatment using levodopa, a precursor to dopamine.

Other symptoms may include parkinsonism, characterized by tremor, rigidity, and bradykinesia. Some individuals may also experience diurnal variation in symptoms, with worsening in the evening. In addition to motor symptoms, some patients may have psychiatric manifestations such as depression or anxiety.

Diagnosis

Diagnosis of autosomal dominant GTP cyclohydrolase I deficiency is based on clinical evaluation, family history, and genetic testing. Measurement of neurotransmitter metabolites in the cerebrospinal fluid (CSF) can support the diagnosis by showing reduced levels of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), which are metabolites of dopamine and serotonin, respectively.

Treatment

The primary treatment for autosomal dominant GTP cyclohydrolase I deficiency is levodopa, which can dramatically improve motor symptoms. The response to levodopa is often rapid and sustained, making it a key diagnostic and therapeutic tool. In some cases, additional supplementation with 5-hydroxytryptophan (5-HTP) or serotonin precursors may be beneficial, particularly if psychiatric symptoms are present.

Prognosis

With appropriate treatment, individuals with autosomal dominant GTP cyclohydrolase I deficiency can lead relatively normal lives. Early diagnosis and treatment are crucial to prevent complications and improve quality of life. The response to levodopa is typically excellent, and many patients experience significant improvement in motor function.

Related pages

• Dystonia
• Levodopa
• Tetrahydrobiopterin
• Dopamine
• Serotonin